BMS-754807

• CAT Number: I000071
• CAS Number: 1001350-96-4
• Molecular Formula: C₂₃H₂₄FN₉O
• Molecular Weight: 461.49
• Purity: ≥95%
• Synonyms: (2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide
• Target: IGF-1R
• Solubility: in DMSO > 10 mM
• Storage: 3 years -20℃ powder
• IC50: 1.8 nM/1.7 nM(IGF-1R/InsR) [1]
• InChI: InChI=1S/C23H24FN9O/c1-23(21(34)26-15-7-8-18(24)25-13-15)9-3-10-32(23)22-28-20(17-4-2-11-33(17)31-22)27-19-12-16(29-30-19)14-5-6-14/h2,4,7-8,11-14H,3,5-6,9-10H2,1H3,(H,26,34)(H2,27,28,29,30,31)/t23-/m0/s1
• InChIKey: LQVXSNNAFNGRAH-QHCPKHFHSA-N
• SMILES: C[C@]1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F

BMS-754807(CAT: I000071) is a potent and selective small-molecule inhibitor targeting the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) signaling pathways. By competitively inhibiting these tyrosine kinases, it disrupts key processes involved in cell proliferation, survival, and metabolism. BMS-754807 is highly relevant in the oncology field, where IGF-1R overexpression is linked to tumor growth and resistance to therapy. This inhibitor is widely utilized in cancer research to evaluate its potential in overcoming resistance mechanisms and enhancing therapeutic outcomes. Its broad application supports investigations into targeted therapies for malignancies and metabolic-related disorders.